Treatment of genotype 1 HCV infection In 2015, six treatment regimens were available for patients with genotype 1 HCV infection, including two regimens containing IFN and four regimens without IFN. The combination regimen of sofosbuvir and ribavirin should not be used in patients with genotype 1 HCV infection in cases where none of the recommended regimens can be applied, according to the previous EASL clinical practice guideline, for the treatment of pegylated interferon (PegIFN)-α and ribavirin duplex or PegIFN-α, ribavirin and telaprevir (telaprevir) or boceprevir Selected patients for whom responses may occur with triplet regimens of prednisolone (boceprevir), these regimens remain acceptable until new direct-acting antivirals (DAAs) are available and affordable. Genotype 1 IFN-containing regimens1 Patients with genotype 1 HCV infection may be treated with a combination regimen of weekly PegIFN-α, daily weight-based ribavirin (1000 or 1200 mg/d for patients <75 kg or ≥75 kg, respectively), and daily sofosbuvir (400 mg/d) for 12 weeks (A1). Genotype 1 IFN-containing regimen2 Patients with genotype 1 HCV infection can be treated with a combination regimen of weekly PegIFN-α, daily weight-based ribavirin (1000 or 1200 mg/d for patients <75 kg or ≥75 kg, respectively), and daily simeprevir (150 mg/d) (A1). This combination regimen is not recommended for patients infected with gene subtype 1a with a Q80K substitution detected in the NS3 protease sequence at baseline, as assessed by population sequencing (direct sequence analysis) (A1). Simeprevir should be administered in combination with PegIFN-α and ribavirin for 12 weeks, followed by an additional 12 weeks of treatment with Peg IFN-α and ribavirin alone (24 weeks total) for primary and previously relapsed patients, including those with cirrhosis, and an additional 36 weeks (48 weeks total) for those with previous partial response or non-response, including those with cirrhosis ( B1). HCV RNA levels at the time of treatment should be monitored and treatment should be discontinued if HCV RNA levels are ≥25 IU/mL at week 4, 12, or 24 of treatment (A2).